Drugs / THB335
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06425861 | May → Dec 2024 | — | Third Harmonic Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THB335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06425861 ↗ |
| Action | Inhibit | “highly potent and selective inhibitor” NCT06425861 ↗ |
| Route | Oral | “THB335 administered orally” NCT06425861 ↗ |
| Target | KIT | “inhibitor of the receptor tyrosine kinase KIT” NCT06425861 ↗ |